Selected Start-Ups (02/01)
Executive Summary
In Vivo summarizes the technology of several recently founded companies: Clinsights Inc. provides web-based post-market clinical and sales support for medical device and pharmaceutical companies and physicians. CombinatoRx Inc. hopes to develop the next generation of pharmaceuticals using new theories of how therapeutics should interact with the complex components of cells. Gyros AB has developed technology for miniaturizing and integrating routine and non-routine laboratory processes on disposable CDs. Innovative Drug Delivery Systems Inc. will develop and commercialize unique nasally administered compounds to treat acute and chronic pain and their associated symptoms. PhytaGenics will use its proprietary rapid, high-volume transgenic production technology to create recombinant biopharmaceutical proteins in plants. StemCo Biomedical Inc.'s stem cell platform is capable of identifying and isolating healthy stem cells from contaminating cells, and can be used in repopulating blood systems or regenerating organs and tissue.
You may also be interested in...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.